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Broadly	  neutralizing	  antibodies	  against	  HIV	  are	  able	  to	  act	  in	  many	  different	  ways	  in	  
vivo:	  they	  can	  block	  viral	  entry,	  clear	  plasma	  virions,	  or	   lead	  to	   the	  death	  of	  virus-­‐expressing	   cells.	   Recently,	   the	   3BNC117	   broadly	   neutralizing	   antibody	   has	   been	  tested	  in	  a	  phase	  1	  clinical	  trial	  as	  a	  potential	  alternative	  treatment	  of	  HIV.	  	  We	  test	  if	   3BNC117	   presents	   with	   one	   or	   a	   combination	   of	   these	   antiviral	   effects	   by	  developing	  a	  pharmacokinetic	  model	  of	  3BNC117	  dynamics	  and	  estimating	  patient’s	  parameters.	  We	   use	   this	  model	   together	   with	   a	   viral	   dynamics	  model	   to	   test	   the	  effects	   of	   3BNC117.	   We	   fit	   the	   viral	   dynamics	   model	   to	   HIV	   RNA	   measurements	  from	   patients	   given	   antibody	   therapy	   and	   conclude	   that	   3BNC117	   elicits	   both	  neutralizing	  and	  non-­‐neutralizing	  effects	  across	  most	  patients.	  We	  predict	   that	  the	  combined	  effects	  of	  initial	  CD4	  T	  cell	  count,	  initial	  HIV	  levels,	  and	  virus	  production	  are	  strong	   indicators	  of	  patient’s	   response	   to	  3BNC117	  as	  an	   immunotherapy.	  We	  end	  by	  modeling	  the	  effect	  of	  antibody	  boosting	  on	  the	  long-­‐term	  HIV	  levels.	  
